BG103219A - Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие - Google Patents

Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие

Info

Publication number
BG103219A
BG103219A BG103219A BG10321999A BG103219A BG 103219 A BG103219 A BG 103219A BG 103219 A BG103219 A BG 103219A BG 10321999 A BG10321999 A BG 10321999A BG 103219 A BG103219 A BG 103219A
Authority
BG
Bulgaria
Prior art keywords
ltb4
antagonistic activity
benzamidine derivatives
activity medicines
medicines
Prior art date
Application number
BG103219A
Other languages
English (en)
Other versions
BG63938B1 (bg
Inventor
Kurt Schromm
Ralf Anderskewitz
Ernst-Otto Renth
Franz Birke
Hans Jennewein
Christopher Meade
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of BG103219A publication Critical patent/BG103219A/bg
Publication of BG63938B1 publication Critical patent/BG63938B1/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/62—Compounds containing any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylcarbamates
    • C07C271/64—Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Изобретението се отнася до нови бензамидинови производни с формула, в която заместителите имат значения, посочени в описанието, до методза тяхното получаване и до използването им в медицината.
BG103219A 1996-09-10 1999-03-01 Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие BG63938B1 (bg)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19636689A DE19636689A1 (de) 1996-09-10 1996-09-10 Neue Benzamidinderivate
PCT/EP1997/004921 WO1998011062A1 (de) 1996-09-10 1997-09-09 Benzamidinderivate und ihre verwendung als arzneimittel mit ltb4-antagonistischer wirkung

Publications (2)

Publication Number Publication Date
BG103219A true BG103219A (bg) 1999-10-29
BG63938B1 BG63938B1 (bg) 2003-07-31

Family

ID=7805125

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103219A BG63938B1 (bg) 1996-09-10 1999-03-01 Бензамидинови производни и използването им като лекарствени средства с ltb4-антагонистично действие

Country Status (30)

Country Link
US (2) US6197824B1 (bg)
EP (2) EP1203764B1 (bg)
JP (2) JP4150427B2 (bg)
KR (1) KR20000036005A (bg)
CN (1) CN1104412C (bg)
AR (1) AR009741A1 (bg)
AT (2) ATE224363T1 (bg)
AU (1) AU727900B2 (bg)
BG (1) BG63938B1 (bg)
BR (1) BR9712816A (bg)
CA (1) CA2262566C (bg)
CO (1) CO4900032A1 (bg)
CZ (1) CZ297252B6 (bg)
DE (3) DE19636689A1 (bg)
DK (1) DK0929516T3 (bg)
EA (1) EA003245B1 (bg)
EE (1) EE04431B1 (bg)
ES (1) ES2184131T3 (bg)
HU (1) HUP9904367A3 (bg)
IL (1) IL128144A (bg)
NO (1) NO312239B1 (bg)
NZ (1) NZ334895A (bg)
PL (1) PL188012B1 (bg)
PT (1) PT929516E (bg)
SK (1) SK282432B6 (bg)
TR (1) TR199900501T2 (bg)
TW (1) TW378200B (bg)
UA (1) UA60315C2 (bg)
WO (1) WO1998011062A1 (bg)
ZA (1) ZA978045B (bg)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1150162C (zh) * 1997-11-20 2004-05-19 帝人株式会社 联苯基脒衍生物
HK1043106A1 (zh) 1998-12-14 2002-09-06 F. Hoffmann-La Roche Ag 苯基甘氨酸衍生物
US6291531B1 (en) * 1999-10-07 2001-09-18 Boehringer Ingelheim Pharma Kg LTB4 antagonist, processes for the preparation thereof and its use as a pharmaceutical composition
DE19948428A1 (de) * 1999-10-07 2001-04-12 Boehringer Ingelheim Pharma Neuer LTB¶4¶-Antagonist, Verfahren zu dessen Herstellung und dessen Verwendung als Arzneimittel
DE10052333A1 (de) * 2000-10-24 2002-05-02 Boehringer Ingelheim Pharma Neue Sulfooxybenzamide
US6528491B2 (en) 2000-10-24 2003-03-04 Boehringer Ingelheim Pharma Kg Pyranoside derivatives
DE10052658A1 (de) * 2000-10-24 2002-05-02 Boehringer Ingelheim Pharma Neue Pyranosidderivate
US6489359B2 (en) 2000-10-24 2002-12-03 Boehringer Ingelheim Pharma Kg Sulphoxybenzamides
US6608054B2 (en) * 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
US7776315B2 (en) * 2000-10-31 2010-08-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions based on anticholinergics and additional active ingredients
AU4239302A (en) * 2001-06-28 2003-01-02 Pfizer Products Inc. Benzoic acid substituted benzopyrans for the treatment of atherosclerosis
IL159493A0 (en) * 2001-07-14 2004-06-01 Boehringer Ingeiheim Pharma Gm Pharmaceutical formulation containing an ltb4 antagonist
US20030119901A1 (en) * 2001-07-14 2003-06-26 Boehringer Ingelheim Pharma Kg Pharmaceutical formulation containing an LTB4 antagonist
MXPA04001153A (es) * 2001-08-31 2005-02-17 Neurochem Int Ltd Derivados de amidina para tratar la amiloidosis.
DE10213350A1 (de) * 2002-03-26 2003-10-16 Boehringer Ingelheim Pharma Verwendung von LTB¶4¶Antagonisten in der Tiermedizin
US6921752B2 (en) * 2002-03-26 2005-07-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of LTB4 antagonists in veterinary medicine
RS20050390A (sr) * 2002-11-26 2008-04-04 Boehringer Ingelheim Pharma Gmbh. & Co.Kg., Farmaceutska kompozicija koja obuhvata ltb4 antagonist i koks-2 inhibitor ili kombinovani koks1/2 inhibitor
US7262223B2 (en) * 2004-01-23 2007-08-28 Neurochem (International) Limited Amidine derivatives for treating amyloidosis
CA2572898C (en) * 2004-07-05 2010-04-20 Dong Wha Pharmaceutical Ind. Co., Ltd. Composition for the prevention and treatment of allergic inflammatory disease
KR20060017929A (ko) * 2004-08-04 2006-02-28 동화약품공업주식회사 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물
US8679288B2 (en) * 2008-06-09 2014-03-25 Lam Research Corporation Showerhead electrode assemblies for plasma processing apparatuses
CN106831611B (zh) * 2017-01-23 2019-06-21 北京化工大学 一种偕胺肟类化合物及其在制备抑制癌细胞增殖药的应用
WO2018207950A1 (ja) 2017-05-12 2018-11-15 横山　茂之 クラスａ ｇｐｃｒ結合性化合物改変体
AU2019350072A1 (en) * 2018-09-24 2021-04-29 The University Of British Columbia Modulation of Granzyme K activity in the treatment of skin conditions
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4102024A1 (de) 1991-01-24 1992-07-30 Thomae Gmbh Dr K Biphenylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0518818A3 (en) * 1991-06-11 1993-04-28 Ciba-Geigy Ag Arylethers, their manufacture and use as medicament
US5246965A (en) 1991-06-11 1993-09-21 Ciba-Geigy Arylethers, their manufacture and methods of treatment
CA2129526A1 (en) 1992-02-05 1993-08-06 Franz Birke Novel amidine derivatives, their preparation and their use as medicaments with ltb4 antagonistic effect
DE4219158A1 (de) 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4424713A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Substituierte Benzamidine, ihre Herstellung und Verwendung als Arnzneistoffe
DE4424714A1 (de) * 1994-07-13 1996-01-18 Boehringer Ingelheim Kg Neue chemische Verbindung, ihre Herstellung und ihre Verwendung als Arnzneistoff
DE19546452A1 (de) * 1995-12-13 1997-06-19 Boehringer Ingelheim Kg Neue Phenylamidinderivate, Verfahren zu ihrer Herstelung und ihre Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US6197824B1 (en) 2001-03-06
DE59708278D1 (de) 2002-10-24
EE04431B1 (et) 2005-02-15
HK1020564A1 (en) 2000-05-12
NZ334895A (en) 2000-09-29
UA60315C2 (uk) 2003-10-15
JP2001504087A (ja) 2001-03-27
NO312239B1 (no) 2002-04-15
IL128144A0 (en) 1999-11-30
CA2262566A1 (en) 1998-03-19
JP4288299B2 (ja) 2009-07-01
CO4900032A1 (es) 2000-03-27
EA199900279A1 (ru) 1999-08-26
AU4383897A (en) 1998-04-02
EE9900086A (et) 1999-10-15
SK282432B6 (sk) 2002-02-05
EA003245B1 (ru) 2003-02-27
DE19636689A1 (de) 1998-03-12
JP2008266333A (ja) 2008-11-06
NO991131L (no) 1999-03-09
EP0929516A1 (de) 1999-07-21
ES2184131T3 (es) 2003-04-01
DE59711625D1 (de) 2004-06-17
BG63938B1 (bg) 2003-07-31
CN1230174A (zh) 1999-09-29
KR20000036005A (ko) 2000-06-26
WO1998011062A1 (de) 1998-03-19
ATE224363T1 (de) 2002-10-15
NO991131D0 (no) 1999-03-09
ATE266630T1 (de) 2004-05-15
CZ82299A3 (cs) 1999-09-15
EP1203764A1 (de) 2002-05-08
SK29699A3 (en) 2000-03-13
JP4150427B2 (ja) 2008-09-17
ZA978045B (en) 1998-03-10
CZ297252B6 (cs) 2006-10-11
EP0929516B1 (de) 2002-09-18
AR009741A1 (es) 2000-05-03
TW378200B (en) 2000-01-01
PL188012B1 (pl) 2004-11-30
AU727900B2 (en) 2001-01-04
BR9712816A (pt) 1999-11-23
US6265612B1 (en) 2001-07-24
HUP9904367A2 (hu) 2000-05-28
PT929516E (pt) 2003-01-31
CN1104412C (zh) 2003-04-02
HUP9904367A3 (en) 2001-11-28
TR199900501T2 (xx) 1999-07-21
DK0929516T3 (da) 2003-01-13
EP1203764B1 (de) 2004-05-12
CA2262566C (en) 2006-07-11
PL332136A1 (en) 1999-08-30
IL128144A (en) 2004-07-25

Similar Documents

Publication Publication Date Title
SE9504661D0 (sv) New compounds
SE9904505D0 (sv) Novel compounds
MX9700885A (es) Nuevas heteroariloxazolidinonas.
TR200100918T2 (tr) Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi
SE9901875D0 (sv) Novel compounds
AU2002218167A1 (en) N-phenyl-2-pyrimidine-amine derivatives
YU57600A (sh) Derivarti biciklične hidroksaminske kiseline
YU49195A (sh) 5-člani heteroaril-oksazolidinoni, njihova upotreba za dobijanje lekova kao i lekovi koji ih sadrže
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
IL94433A0 (en) Aminophenol derivatives,their preparation and pharmaceutical compositions containing them
BG103399A (bg) Нови заместени с хетероцикъл бензамиди и тяхното използване за лечение на болести
EA199900279A1 (ru) Производные бензамида и их применение в качестве лекарственных средств с лтв4-антагонистической активностью
MY115211A (en) Novel amino acid derivatives, their preparation and use
BG100069A (bg) Амидинови производни,съдържащи хетероциклични групи,получаване и приложението им
BG102623A (bg) Нови производни на бензоилгуанидина, методи за тяхното получаване и приложението им за производството на ле- карствени средства
MY133112A (en) 3-amino-3-arylpropan-1-ol derivatives, and their preparation and use
BG101605A (bg) Ентерокинетични бензамиди
BG104232A (bg) Заместени 1,2,3,4,5,6-хексахидро-2,6-метано-3-бензазоцин- 10-оли, метод за тяхното получаване и приложението им като лекарствени средства
BG101220A (bg) N-заместени 3-азабицикло(3.2.0) хептанови производни, метод за получаване и използването им
TR200100637T2 (tr) Yeni doğal ürün türevleri
BG50159A3 (bg) Метод за получаване на производни на пиранобензоксадиазол
BG102707A (bg) Нови триазолопурини, метод за тяхното получаване и тяхното приложение като лекарствени средства
SE9504662D0 (sv) New compounds
DK0505400T3 (da) N-substituerede naphthalimider, deres fremstilling og anvendelse
TR199900013T2 (xx) Yeni bile�ikler.